brewcrew4you wrote:"The study followed 81 patients with serious skin cancer: 28 received the standard chemotherapy drug paclitaxel and lived an average of 1.8 months before their cancer worsened, while 53 got paclitaxel plus the new drug and lived an average of 3.7 months before the disease worsened.
Patients on the experimental combination survived an average of one year after being diagnosed while those getting only the standard treatment survived an average of 7.8 months."
Not exactly a miracle cure...
You have to remember that they typically don't give experimental drugs to non-terminal cancer patients. Most of these studies you'll read about show that the people who get these drugs live only a few months more than the control group. They do not approach non-terminal cancer patients for experimental therapies.
As a husband of a cancer survivor (three years and counting
) I have some knowledge of this kind of stuff. I'm also greatly interested in any advances they make.
Basically I told my wife that she needed to give me five years, and by then they'd have another Magic Bullet. This could very well be a step in the right direction.